Vinpocetine inhibits NF-[kappa]B-dependent inflammation via an IKK-dependent but PDE-independent mechanism

Citation metadata

Publisher: National Academy of Sciences
Document Type: Author abstract; Report
Length: 217 words

Document controls

Main content

Abstract :

Inflammation is a hallmark of many diseases, such as atherosclerosis, chronic obstructive pulmonary disease, arthritis, infectious diseases, and cancer. Although steroids and cyclooxygenase inhibitors are effective antiinflammatory therapeutical agents, they may cause serious side effects. Therefore, developing unique antiinflammatory agents without significant adverse effects is urgently needed. Vinpocetine, a derivative of the alkaloid vincamine, has long been used for cerebrovascular disorders and cognitive impairment. Its role in inhibiting inflammation, however, remains unexplored. Here, we show that vinpocetine acts as an antiinflammatory agent in vitro and in vivo. In particular, vinpocetine inhibits TNF-[alpha]-induced NF-[kappa]B activation and the subsequent induction of proinflammatory mediators in multiple cell types, including vascular smooth muscle cells, endothelial cells, macrophages, and epithelial cells. We also show that vinpocetine inhibits monocyte adhesion and chemotaxis, which are critical processes during inflammation. Moreover, vinpocetine potently inhibits TNF-[alpha]- or LPS-induced up-regulation of proinflammatory mediators, including TNF-[alpha], IL-1[beta], and macrophage inflammatory protein-2, and decreases interstitial infiltration of polymorphonudear leukocytes in a mouse model of TNF-[alpha]- or LPS-induced lung inflammation. Interestingly, vinpocetine inhibits NF-[kappa]B-dependent inflammatory responses by directly targeting IKK, independent of its well-known inhibitory effects on phosphodiesterase and [Ca.sup.2+] regulation. These studies thus identify vinpocetine as a unique antiinflammatory agent that may be repositioned for the treatment of many inflammatory diseases. vinpocetine | inflammation | NF-[kappa]B | IKK

Source Citation

Source Citation   

Gale Document Number: GALE|A228330348